Much to the disappointment of many gout patients, febuxostat was not approved in the U.S. More studies are underway so I expect it will be a least a couple of years. I do not know where it is in the approval process for New Zealand.
About Alan Matsumoto, M.D.
Part-time Faculty, Division of Rheumatology
Johns Hopkins University